AAPL   320.20 (+0.66%)
MSFT   182.33 (+0.17%)
FB   225.54 (-1.65%)
GOOGL   1,425.31 (+0.35%)
AMZN   2,411.93 (+0.06%)
NVDA   340.17 (+0.99%)
CGC   21.65 (+8.25%)
MU   46.65 (-5.66%)
GE   6.82 (-6.45%)
AMD   51.92 (-1.55%)
T   31.10 (-2.35%)
GILD   75.46 (+0.75%)
DIS   116.64 (-4.02%)
BAC   25.00 (-3.77%)
BA   150.18 (+0.44%)
AAPL   320.20 (+0.66%)
MSFT   182.33 (+0.17%)
FB   225.54 (-1.65%)
GOOGL   1,425.31 (+0.35%)
AMZN   2,411.93 (+0.06%)
NVDA   340.17 (+0.99%)
CGC   21.65 (+8.25%)
MU   46.65 (-5.66%)
GE   6.82 (-6.45%)
AMD   51.92 (-1.55%)
T   31.10 (-2.35%)
GILD   75.46 (+0.75%)
DIS   116.64 (-4.02%)
BAC   25.00 (-3.77%)
BA   150.18 (+0.44%)
AAPL   320.20 (+0.66%)
MSFT   182.33 (+0.17%)
FB   225.54 (-1.65%)
GOOGL   1,425.31 (+0.35%)
AMZN   2,411.93 (+0.06%)
NVDA   340.17 (+0.99%)
CGC   21.65 (+8.25%)
MU   46.65 (-5.66%)
GE   6.82 (-6.45%)
AMD   51.92 (-1.55%)
T   31.10 (-2.35%)
GILD   75.46 (+0.75%)
DIS   116.64 (-4.02%)
BAC   25.00 (-3.77%)
BA   150.18 (+0.44%)
AAPL   320.20 (+0.66%)
MSFT   182.33 (+0.17%)
FB   225.54 (-1.65%)
GOOGL   1,425.31 (+0.35%)
AMZN   2,411.93 (+0.06%)
NVDA   340.17 (+0.99%)
CGC   21.65 (+8.25%)
MU   46.65 (-5.66%)
GE   6.82 (-6.45%)
AMD   51.92 (-1.55%)
T   31.10 (-2.35%)
GILD   75.46 (+0.75%)
DIS   116.64 (-4.02%)
BAC   25.00 (-3.77%)
BA   150.18 (+0.44%)
Log in

LON:DPHDechra Pharmaceuticals Share Price, Forecast & News

GBX 2,800
+18.00 (+0.65 %)
(As of 05/28/2020 03:46 PM ET)
Add
Compare
Today's Range
2,748
Now: GBX 2,800
2,844
50-Day Range
2,392
MA: GBX 2,704.44
2,936
52-Week Range
388
Now: GBX 2,800
3,090
Volume351,380 shs
Average Volume282,452 shs
Market Capitalization£2.88 billion
P/E Ratio100.72
Dividend Yield1.15%
BetaN/A
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development segments. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and locomotion and pain management products for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for dogs and cats under the Specific brand; distributes veterinary pharmaceuticals and equipment; and offers financial services. The company markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More
Dechra Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1606-814730

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£498.90 million
Cash FlowGBX 61.82 per share
Book ValueGBX 464.10 per share

Profitability

Miscellaneous

Employees1,437
Market Cap£2.88 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive DPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DPH and its competitors with MarketBeat's FREE daily newsletter.

Dechra Pharmaceuticals (LON:DPH) Frequently Asked Questions

How has Dechra Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Dechra Pharmaceuticals' stock was trading at GBX 2,472 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DPH shares have increased by 13.3% and is now trading at GBX 2,800. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Dechra Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dechra Pharmaceuticals.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals declared a dividend on Monday, February 24th. Shareholders of record on Thursday, March 5th will be paid a dividend of GBX 10.29 per share on Wednesday, April 8th. This represents a yield of 0.37%. The ex-dividend date of this dividend is Thursday, March 5th. The official announcement can be viewed at this link. View Dechra Pharmaceuticals' dividend history.

What price target have analysts set for DPH?

4 analysts have issued 12 month price objectives for Dechra Pharmaceuticals' stock. Their forecasts range from GBX 2,560 to GBX 3,300. On average, they anticipate Dechra Pharmaceuticals' stock price to reach GBX 2,968.75 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View analysts' price targets for Dechra Pharmaceuticals.

Has Dechra Pharmaceuticals been receiving favorable news coverage?

Press coverage about DPH stock has trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dechra Pharmaceuticals earned a news impact score of -3.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutDechra Pharmaceuticals.

Who are some of Dechra Pharmaceuticals' key competitors?

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), Supergroup (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SkyePharma (SKP) and Barratt Developments (BDEV).

Who are Dechra Pharmaceuticals' key executives?

Dechra Pharmaceuticals' management team includes the following people:
  • Mr. Ian D. Page, CEO, MD & Exec. Director (Age 58)
  • Mr. Richard John Cotton, CFO & Director (Age 58)
  • Dr. Anthony Gerard Griffin, MD of Dechra Veterinary Products for Europe & Exec. Director (Age 56)
  • Ms. Katy Clough, Group HR Director
  • Mr. Mike Eldred, Pres of North America (Age 49)

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 2,800.

How big of a company is Dechra Pharmaceuticals?

Dechra Pharmaceuticals has a market capitalization of £2.88 billion and generates £498.90 million in revenue each year. Dechra Pharmaceuticals employs 1,437 workers across the globe.

What is Dechra Pharmaceuticals' official website?

The official website for Dechra Pharmaceuticals is www.dechra.com.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company can be reached via phone at +44-1606-814730.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.